Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Nishimoto

Showing results (11-20 of 14) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 14 results.
Cancer|April 16, 2017
Immune responses and long-term disease recurrence status after telomerase-based dendritic cell immunotherapy in patients with acute myeloid leukemiaHanna J Khoury, Robert H Collins, William Blum, et al.
Journal for Immunotherapy of Cancer|December 17, 2021
Off-the-shelf Vδ1 gamma delta T cells engineered with glypican-3 (GPC-3)-specific chimeric antigen receptor (CAR) and soluble IL-15 display robust antitumor efficacy against hepatocellular carcinomaAmani Makkouk, Xue Cher Yang, Taylor Barca, et al.
Clinical & Translational Immunology|February 9, 2022
Allogeneic CD20-targeted γδ T cells exhibit innate and adaptive antitumor activities in preclinical B-cell lymphoma modelsKevin P Nishimoto, Taylor Barca, Aruna Azameera, et al.
Journal for Immunotherapy of Cancer|July 1, 2025
ADI-270: an armored allogeneic gamma delta T cell therapy designed to target CD70-expressing solid and hematologic malignanciesKevin P Nishimoto, Gauri Lamture, Yvan Chanthery, et al.
Pageof 2

Showing results (11-20 of 14) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 14 results.
Cancer|April 16, 2017
Immune responses and long-term disease recurrence status after telomerase-based dendritic cell immunotherapy in patients with acute myeloid leukemiaHanna J Khoury, Robert H Collins, William Blum, et al.
Journal for Immunotherapy of Cancer|December 17, 2021
Off-the-shelf Vδ1 gamma delta T cells engineered with glypican-3 (GPC-3)-specific chimeric antigen receptor (CAR) and soluble IL-15 display robust antitumor efficacy against hepatocellular carcinomaAmani Makkouk, Xue Cher Yang, Taylor Barca, et al.
Clinical & Translational Immunology|February 9, 2022
Allogeneic CD20-targeted γδ T cells exhibit innate and adaptive antitumor activities in preclinical B-cell lymphoma modelsKevin P Nishimoto, Taylor Barca, Aruna Azameera, et al.
Journal for Immunotherapy of Cancer|July 1, 2025
ADI-270: an armored allogeneic gamma delta T cell therapy designed to target CD70-expressing solid and hematologic malignanciesKevin P Nishimoto, Gauri Lamture, Yvan Chanthery, et al.
Pageof 2